Interview with Oleg Epstein, General Director, Materia Medica
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
Address: 9 bld, 3rd Samotyochnyi per., Moscow, 127 473,Russia
Tel: +7 495 684 43 33
Web: http://www.materiamedica.ru/ru/
Research and manufacturing company Materia Medica Holding is one of the top Russian pharmaceutical companies. For more than 10 years Materia Medica Holding has been carrying out fundamental research in the pharmacology of ultra low doses and currently the company holds the leading position in this field. The researchers of the Company were the first to conduct systemic studies of ultra dilute solutions.
Company’s product portfolio includes OTC drugs of different pharmacological groups, such as immunomodulators, antiviral products and anti-inflammatory drugs(Anaferon for children, Anaferon, Ergoferon), sedative drugs, nootropics and stress – protective drugs (Tenoten, Tenoten for children), weight reduction drugs (Dietressa), regulators of the urogenital system and reproductive system functions(Afala, Impaza), the drugs for treatment of diseases of joints (Arthrofoon), and of alcohol addiction (Proproten-100). The products are marketed in Russia, the CIS countries, Europe, Asia and Latin America. The Company is constantly searching for new areas where the drugs containing ultra low doses of antibodies can be used.
The efforts of the company’s staff for development and introduction into medical practice of new highly effective remedies based on ultra low doses of antibodies to endogenous regulators were recognized with Science & Technology Award 2005 and Science & Technology Award 2006 by Government of the Russia (orders of the Government of the Russia No. 96 dd. February 20th , 2006 AND No. 12 dd. February 22nd , 2007).
The staff of Materia Medica Holding exceeds 600 people. The company has its own production site in Chelyabinsk equipped with the up-to-date GMP-compliant facilities of European manufacturers.
Materia Medica Holding actively carries on cooperation with the leading Russian and foreign research institutions aimed at conducting new studies and to obtaining clinical data.
Materia Medica Holding drugs have become known not only in Russia but also abroad. In many countries marketing authorizations for our drugs have been issued. At present the Company has expanded its activity on FSU, Europe, Asia and Latin America markets. Our affiliate company as well as our representative offices in Belarus, Uzbekistan and Kazakhstan carries out our products presentation.
We strive for developing highly efficient drugs ensuring effective treatment, prophylaxis and rehabilitation in different areas of medicine. We are sure that our drug can help millions of people to protect their health.
Currently, Materia Medica Holding manufactures more than thirty drugs and 8 of them are original products:
Anaferon — an effective drug for prevention and treatment of influenza and SARS.
Anaferon for children— the product was specially developed for treatment and prevention of influenza, SARS and other viral infections in children.
Arthrofoon — a drug for course treatment of chronic inflammatory diseases of joints (rheumatic arthritis, osteoarthritis).
Afala — a drug for treatment of prostatitis and benign prostate hyperplasia (BHP). It reduces oedema and inflammation in tissues, improves prostate functioning.
Impaza — a product for course treatment of erectile dysfunction of different etiology, increases libido and erection.
Proproten-100 — a drug used for treatment of alcoholism, reduces desire to drink and improves withdrawal symptoms. The drug efficiently eliminates the main withdrawal symptoms such as faintness, weakness, tremor, shiver, headache, irritability and insomnia.
Tenoten — it is recommended in case of acute and chronic stresses and neurosis-like conditions. It causes no drowsiness during the day, removes anxiety, and improves memory and attention.
Tenoten for children – t is recommended for children, for the treatment of Attention deficit hyperactivity disorder (ADHD).
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here